Author

Hui Wang

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non-Small Cell Lung Cancer: The R-ALPS Randomized Clinical Trial.

This randomized clinical trial found that benmelstobart with or without anlotinib significantly improved progression-free survival (PFS) compared with placebo and adding anlotinib did not significantly improve PFS compared with benmelstobart alone and increased severe and fatal treatment-related adverse events.

Yong-Ling Ji, Qi-Wen Li, Long Chen et al. · JAMA Oncology · 0 citations

Open access Sep 2026

Computed tomography-derived body composition and early changes predict outcomes of first-line chemo-immunotherapy in recurrent/metastatic nasopharyngeal carcinoma

Abstract Background Reliable biomarkers for risk stratification and treatment monitoring in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) treated with first-line chemo-immunotherapy remain limited. This study evaluated the prognostic value of baseline computed tomography (CT)-derived body composition paramete...

Xia Gan, Zheng-Zheng Yu, Ya-Ning Tang et al. · The Oncologist · 0 citations

Case report Open access Sep 2026

A collision tumor of buccal squamous cell carcinoma and diffuse large B-cell lymphoma: a case report and literature review

This case highlights the need to consider a second primary malignancy when the distribution of lesions does not follow the expected metastatic pathway of head and neck SCC and illustrates the limitations of needle biopsy in lymphoid lesions arising in a background of chronic inflammation.

Xiao Pang, Y. Long, Hui Wang et al. · Frontiers in Oncology · 0 citations